24/7 Market News Snapshot 02 September, 2025 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

September 2, 2025

DENVER, Colo., 02 September, 2025 (www.247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) is experiencing a significant surge in market activity, trading at $1.393, reflecting an impressive increase of over 20% from its previous closing price of $1.160. The pre-market session shows robust trading volume, exceeding 7.21 million shares, indicative of strong investor confidence and enthusiasm in the stock. This bullish trend positions the company favorably for a potentially vibrant trading day, prompting traders and investors to monitor developments closely for emerging opportunities.

Concurrently, Hoth Therapeutics has unveiled promising results from preclinical studies concerning its innovative precision antisense candidate, HT-KIT. These findings suggest that HT-KIT could drastically enhance treatment outcomes for patients afflicted with KIT-driven cancers. The studies revealed HT-KIT’s remarkable anti-tumor efficacy in preclinical models, particularly demonstrating rapid tumor cell death in gastrointestinal stromal tumors (GIST) and systemic mastocytosis. Notably, substantial tumor shrinkage was detected within just 24 hours post-treatment, alongside an 80% reduction in KIT expression, the key driver of several aggressive cancers.

Moreover, HT-KIT displayed a favorable safety profile in multi-dose studies, showing no off-target toxicity to critical organs. The biological response was dose-dependent, revealing significant liver engagement while confirming the absence of gross pathology. The bioanalytical results, conducted under Good Laboratory Practice (GLP) standards by Altasciences Company, Inc., underscored HT-KIT’s regulatory-grade validation, with a notable serum stability duration of 37 days at -80°C, exceeding established benchmarks.

Robb Knie, CEO of Hoth Therapeutics, expressed optimism about these results, emphasizing the combination of rapid tumor kill and robust safety as compelling factors in advancing toward IND submission and initiating first-in-human trials. As Hoth moves forward with its pivotal advancements, the biotechnology sector keenly anticipates the company’s next steps in this groundbreaking approach to treatment.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.